CA3188184A1 - Biomarker combinations for determining aggressive prostate cancer - Google Patents
Biomarker combinations for determining aggressive prostate cancerInfo
- Publication number
- CA3188184A1 CA3188184A1 CA3188184A CA3188184A CA3188184A1 CA 3188184 A1 CA3188184 A1 CA 3188184A1 CA 3188184 A CA3188184 A CA 3188184A CA 3188184 A CA3188184 A CA 3188184A CA 3188184 A1 CA3188184 A1 CA 3188184A1
- Authority
- CA
- Canada
- Prior art keywords
- psa
- aggressive
- cap
- population
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Data Mining & Analysis (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Databases & Information Systems (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020902212A AU2020902212A0 (en) | 2020-06-30 | Biomarker combinations for determining aggressive prostate cancer | |
| AU2020902212 | 2020-06-30 | ||
| PCT/AU2021/050705 WO2022000041A1 (en) | 2020-06-30 | 2021-06-30 | Biomarker combinations for determining aggressive prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188184A1 true CA3188184A1 (en) | 2022-01-06 |
Family
ID=79317588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188184A Pending CA3188184A1 (en) | 2020-06-30 | 2021-06-30 | Biomarker combinations for determining aggressive prostate cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230305009A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4172629A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023531567A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021298661A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188184A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022000041A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023366061A1 (en) * | 2022-10-20 | 2025-05-29 | Minomic International Ltd. | Methods for detecting aggressive prostate cancer |
| CN121101470B (zh) * | 2025-09-08 | 2026-05-12 | 简勇 | 一种癌症危险程度辨别方法和系统 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007035766A2 (en) * | 2005-09-19 | 2007-03-29 | The Johns Hopkins University | Biomarker for prostate cancer |
| CA3011988A1 (en) * | 2016-01-22 | 2017-07-27 | Otraces Inc. | Systems and methods for improving disease diagnosis |
| JP7240674B2 (ja) * | 2017-09-29 | 2023-03-16 | Ｍｇｃウッドケム株式会社 | 前立腺癌の検出方法 |
| EP3861348A4 (en) * | 2018-10-05 | 2022-07-20 | Minomic International Ltd. | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER |
-
2021
- 2021-06-30 AU AU2021298661A patent/AU2021298661A1/en active Pending
- 2021-06-30 EP EP21831826.9A patent/EP4172629A4/en active Pending
- 2021-06-30 CA CA3188184A patent/CA3188184A1/en active Pending
- 2021-06-30 JP JP2023523315A patent/JP2023531567A/ja active Pending
- 2021-06-30 WO PCT/AU2021/050705 patent/WO2022000041A1/en not_active Ceased
- 2021-06-30 US US18/010,108 patent/US20230305009A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023531567A (ja) | 2023-07-24 |
| EP4172629A1 (en) | 2023-05-03 |
| US20230305009A1 (en) | 2023-09-28 |
| EP4172629A4 (en) | 2024-07-10 |
| WO2022000041A1 (en) | 2022-01-06 |
| AU2021298661A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12618843B2 (en) | Biomarker combinations for determining aggressive prostate cancer | |
| CA2516795C (en) | Circulating tumor cells (ctc's): early assessment of time to progression,_survival and response to therapy in metastatic cancer patients | |
| TWI698639B (zh) | 前列腺抗原標準品及其用途 | |
| Zheng et al. | Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer | |
| US20230305009A1 (en) | Biomarker combinations for determining aggressive prostate cancer | |
| AU2016297676B2 (en) | Biomarker combinations for prostate disease | |
| JP2016513809A (ja) | 大腸直腸癌の予後を判定する方法 | |
| US11448650B2 (en) | Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers | |
| Partyka et al. | A comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification | |
| US20190361027A1 (en) | Methods for determining breast cancer risk | |
| CN109696547B (zh) | 一种判断结直肠癌预后的标志物及其应用 | |
| US11791043B2 (en) | Methods of prognosing early stage breast lesions | |
| WO2024082026A1 (en) | Methods for detecting aggressive prostate cancer | |
| US20190265243A1 (en) | Biomarkers of therapeutic responsiveness | |
| Margolis et al. | Clinical Performance of the ExoDx (EPI) Prostate Intelliscore Test to Predict High-grade Prostate Cancer at Initial Biopsy: A Pooled Analysis of Three Independent Prospective Studies. | |
| HK1250257B (en) | Biomarker combinations for prostate disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240806 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250619 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250619 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250619 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250623 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250624 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250624 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250826 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250826 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250826 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250826 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250827 |